Amgen Inc (AMG) Stock Price & News

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia

About Amgen Inc

CEORobert A. Bradway

Employees३१.५ हजार

Founded१९८०

Headquartersथाउजेन्ड ओक्स, क्यालिफोर्निया, संयुक्त राज्य अमेरिका

Sector-

Websiteamgen.com

Revenue

Net income

All values in USD	२०२५ सेप्टेम्बर	२०२५ डिसेम्बर	२०२६ मार्च	२०२६ जुन
Revenue	९.५६ अरब	९.८७ अरब	८.६२ अरब	१०.०५ अरब
Cost of goods sold	२.७४ अरब	२.६८ अरब	२.५० अरब	२.७५ अरब
Cost of revenue	२.७४ अरब	२.६८ अरब	२.५० अरब	२.७५ अरब
Research and development expenses	१.९० अरब	२.१४ अरब	१.७२ अरब	१.८७ अरब
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	१.७२ अरब	१.९५ अरब	१.६० अरब	१.७४ अरब
Operating expense	३.५५ अरब	४.१८ अरब	३.२१ अरब	३.७३ अरब
Total operating expenses	६.२९ अरब	६.८५ अरब	५.७० अरब	६.४८ अरब
Operating income	३.२६ अरब	३.०१ अरब	२.९१ अरब	३.५७ अरब
Other non operating income	१८.१० करोड	१४.३० करोड	१९.२० करोड	१४.५० करोड
EBT including unusual items	३.९२ अरब	१.५१ अरब	२.०८ अरब	२.७७ अरब
EBT excluding unusual items	२.७२ अरब	२.५१ अरब	२.३७ अरब	३.०६ अरब
Income tax expense	७०.५० करोड	१८.१० करोड	२६.५० करोड	३९.३० करोड
Effective tax rate	१७.९८%	११.९६%	१२.७२%	१४.२०%
Other operating expenses	-७.१० करोड	८.२० करोड	-११.३० करोड	११.६० करोड
Net income	३.२२ अरब	१.३३ अरब	१.८२ अरब	२.३८ अरब
Net profit margin	३३.६५%	१३.५१%	२१.११%	२३.६२%
Earnings per share	५.६४	५.२९	५.१५	६.२९
Interest and investment income	-	४०.८० करोड	-	-
Interest expense	-६८.५० करोड	-१.०६ अरब	-६५.७० करोड	-६७.३० करोड
Net interest expenses	-६८.५० करोड	-६५.३० करोड	-६५.७० करोड	-६७.३० करोड
Depreciation and amortization charges	-	-	-	-
EBITDA	४.५७ अरब	४.०२ अरब	४.०३ अरब	४.६९ अरब
Gain or loss from assets sale	-	-	-	-

Ask anything